Political Friendster - Rate Connection - Monsanto connected to Novartis
Monsanto |
 |
|
|
|
Novartis |
 |
|
|
|
| Rate the Monsanto - Novartis connection |
|
| SAINT LOUIS, Aug. 3 /PRNewswire-FirstCall/ -- Monsanto Company
announced today that it has filed an arbitration claim against Sandoz, a
subsidiary of the pharmaceutical company Novartis AG, in an international
arbitration proceeding. | | Submitted by fedup | 2007-08-20 03:03:45 | Monsanto Seeks Over $100 Million in Damages Arising From Novartis Subsidiary Failure to Meet FDA Quality Standards
Quality assurance failures and FDA regulatory action at Sandoz facility in
Austria cause significant financial injury for Monsanto
SAINT LOUIS, Aug. 3 /PRNewswire-FirstCall/ -- Monsanto Company
announced today that it has filed an arbitration claim against Sandoz, a
subsidiary of the pharmaceutical company Novartis AG, in an international
arbitration proceeding. Monsanto seeks to recover damages caused by
Sandoz's inadequate quality assurance program and the U.S. Food and Drug
Administration (FDA) issuance of a Warning Letter to Sandoz's
pharmaceutical facility in Kundl, Austria, which contracted to supply
Monsanto's dairy product, POSILAC bovine somatotropin. All products sold by
Monsanto met quality control standards, but the process of making necessary
changes and improvements to the facility limited manufacturing
capabilities.
Supplies to Monsanto and its customers were disrupted as a result of
Sandoz's failure to meet quality assurance obligations that were warranted
and represented by Sandoz as satisfying compliance with FDA's current Good
Manufacturing Practices standards.
In November 2003, the FDA inspected the Sandoz manufacturing facility
in Kundl, Austria, and found problems with the facility and systems that
led to the issuance of an FDA Warning Letter. The process of making
necessary changes and corrections addressed quality assurance, but required
shut-downs and limited manufacturing capabilities at the Sandoz plant. FDA
conducted a follow-up regulatory inspection in 2006 and lifted its Warning
Letter in August 2006.
"Sandoz's failure to maintain the quality practices expected by FDA was
a clear breach of its contractual obligations ," said David Snively, senior
vice president and general counsel for Monsanto. "Since discussions with
Sandoz to resolve this issue were inconclusive, we have filed for
arbitration with the International Chamber of Commerce, according to the
provisions of the contract, seeking in excess of $100 million in damages.
Arbitration will determine how much compensation is owed by Sandoz to
Monsanto."
The arbitration complaint notes that as a direct result of Sandoz's
quality assurance failures, it did not fulfill its contractual supply
agreements and Monsanto suffered extensive financial loss.
Since Monsanto's dairy industry product was first sold in the U.S. in
1994, POSILAC has become the leading dairy animal pharmaceutical supplement
in the United States. Supplementing dairy cows with POSILAC safely enhances
milk production and serves as an important tool to help dairy producers of
all sizes improve the efficiency of their operations. Cows supplemented
with POSILAC produce an average of 10 lb. more milk per day.
Monsanto Company is a leading provider of technology-based solutions
and agricultural products that improve farm productivity and food quality.
For more information on Monsanto, see http://www.monsanto.com.
Cautionary Statements Regarding Forward-Looking Information:
Certain statements contained in this release are "forward-looking
statements," such as statements concerning the company's anticipated
financial results, current and future product performance, regulatory
approvals, business and financial plans and other non-historical facts.
These statements are based on current expectations and currently available
information. However, since these statements are based on factors that
involve risks and uncertainties, the company's actual performance and
results may differ materially from those described or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, among others: continued competition in seeds, traits
and agricultural chemicals; the company's exposure to various
contingencies, including those related to intellectual property protection,
regulatory compliance and the speed with which approvals are received, and
public acceptance of biotechnology products; the success of the company's
research and development activities; the outcomes of major lawsuits,
including proceedings related to Solutia Inc.; developments related to
foreign currencies and economies; successful completion and operation of
recent and proposed acquisitions; fluctuations in commodity prices;
compliance with regulations affecting our manufacturing; the accuracy of
the company's estimates related to distribution inventory levels; the
company's ability to fund its short-term financing needs and to obtain
payment for the products that it sells; the effect of weather conditions,
natural disasters and accidents on the agriculture business or the
company's facilities; and other risks and factors detailed in the company's
filings with the SEC. Undue reliance should not be placed on these
forward-looking statements, which are current only as of the date of this
release. The company disclaims any current intention or obligation to
update any forward-looking statements or any of the factors that may affect
actual results.
SOURCE Monsanto Company
Link to this page:
Link to this page
Back to Topback to top
Related links:
# http://www.monsanto.com
# http://www.prnewswire.com/comp/114341.html/
|
| | Edit |
|
|
|
|
|
|
|
